Navigation Links
NeurogesX to Present at JMP Securities Healthcare Focus Conference
Date:10/1/2009

mbination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but a
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
(Date:12/20/2014)... Parker & Sons, Inc. a focused ... experience in contractor services announces reaching a milestone by ... homeowners of Arizona. Parker and Sons is comprised of ... that make customer service the number one priority. The ... started with one service vehicle and has since grown ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... 2014 Energy Textiles is excited ... available. Celliant, the world’s leading responsive textile, can ... , There are a number of benefits to ... oxygenation and balanced body temperature; which can lead ... relief; enhanced athletic performance; and overall wellness. In ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 SuperCloset raises ... SuperClone Rooms. SuperCloset continues to offer indoor growers the ... one of the new SuperClone Rooms with the award ... and turnkey indoor hydroponic grow room setup. , The ... world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... December 20, 2014 An evening dress is ... a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled ... beautiful dresses in this great shopping platform. Customers can ... the staff's hard work, Discount-Dress.com has been accepted and praised ... faster and easier shopping stage for clients. In order to ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2
... also Establishes New Site Leadership Team at Cambridge ... Continuing the,solidification of its role as the global ... that Andrew D. Skibo has joined the company,as ... a 19-year,veteran of the company, has been promoted ...
... Philadelphia, PA, December 20, 2007 For U.S. veterans ... health functioning are associated with an increased risk of ... of the journal General Hospital Psychiatry. , "Our findings ... for mental health functioning as a risk factor and ...
... tests, so have advanced disease , , THURSDAY, Dec. 20 ... have health insurance are more likely to die because ... so are typically diagnosed with advanced disease, a new ... finding proffers strong evidence that differences in cancer survival ...
... WOODCLIFF LAKE, N.J., Dec. 20 Par,Pharmaceutical Companies, Inc. ... and Exchange Commission (SEC) its Form 10-Q for the ... for this period had been,delayed due to the work ... periods, which were filed earlier this year.,As a result ...
... Exchange Symbol: AKL, MONTREAL, Dec. 20 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation and ... market,conditions, particularly in the small and micro-cap sector, ... initiative. The Company is currently,contemplating other financing options. ...
... Data Show PROMACTA Significantly Raised Platelet Counts and,Lowered ... Treatment of,Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP), ... GSK ; London) today announced the submission ... States Food and Drug Administration,(FDA) for approval to ...
Cached Medicine News:Health News:MedImmune Expands Scientific and Engineering Leadership 2Health News:MedImmune Expands Scientific and Engineering Leadership 3Health News:MedImmune Expands Scientific and Engineering Leadership 4Health News:MedImmune Expands Scientific and Engineering Leadership 5Health News:Mental health linked to amputation risk in diabetic veterans 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 3Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 2Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 3Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 5Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 6Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 7Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 8Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 9Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 10Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 11Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 12Health News:Akela Pharma provides corporate update 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 3Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 4Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 5
Porous foundation 440 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
The cemented hip joint prosthesis system....
The uncemented hip joint prosthesis system...
Medicine Products: